Vemlidy dominates stagnant 300 bil. won hepatitis B market
By Son, Hyung-Min | translator Kim, Jung-Ju
24.01.26 12:09:53
가나다라
0
Vemlidy has exceeded 60 million won in sales, leading growth in the prescription market for original pharmaceuticals
The market for Viread and Baraclude, original pharmaceuticals other than Vemlidy, is slowing down
Generics seen a slight decrease in prescription sales, with about a 6% decrease compared to last year
The market for hepatitis B treatment, worth 300 billion won annually, is currently experiencing a slowdown. While Gilead Sciences Korea’s Vemlidy is expanding its market share, Viread and Baraclude are facing a decline. In the generics market, Dong-A ST is leading the market.
Prescription sales for Vemlidy has increased by 26% compared to last year, while original drugs have shown poor performance
According to the drug market research agency UBIST on the 26th, the market size for hospital outpatient prescriptions last year was 284.6 billion won, a 1.2% increase compared to 281.1 billion won in 2022. Additionally, the market size for original drugs last year was 236 billion won, show
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)